Immix Biopharma (Immix Biopharma) Debt-to-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma Debt-to-Asset?

Immix Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.03 Mil. Immix Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.06 Mil. Immix Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $34.35 Mil. Immix Biopharma's debt to asset for the quarter that ended in Mar. 2024 was 0.03.

Immix Biopharma Debt-to-Asset Historical Data

The historical data trend for Immix Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Debt-to-Asset Chart

Immix Biopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

4.35

7.59

Immix Biopharma Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial												-	-	-	-	0.03

Competitive Comparison of Immix Biopharma's Debt-to-Asset

For the Biotechnology subindustry, Immix Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immix Biopharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's Debt-to-Asset falls into.

Immix Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Immix Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	19.925
	=	0.00

Immix Biopharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.034	+	1.059)	/	34.348
	=	0.03

Immix Biopharma (NAS:IMMX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Immix Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Immix Biopharma (Immix Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064

Website

https://www.immixbio.com

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.

Executives

Jason Hsu	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Helen C. Adams	director	15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan	director	1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky	director, 10 percent owner	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Ilya M Rachman	director, officer: CEO and Chairman	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris	director, officer: Chief Financial Officer	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Sean Senn	10 percent owner	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin	officer: Scientific Co-Founder	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross	officer: CMO & Head of Clinical Dev.	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064